BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21617727)

  • 1. Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity.
    Stoyianni A; Kapodistrias N; Kampletsas E; Pentheroudakis G; Pavlidis N
    Tumori; 2011; 97(2):252-5. PubMed ID: 21617727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin.
    Grosso F; D'Incalci M
    Tumori; 2011; 97(2):256. PubMed ID: 21617728
    [No Abstract]   [Full Text] [Related]  

  • 3. Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma.
    Skorupa A; Beldner M; Kraft A; Montero AJ
    Cancer Biol Ther; 2007 Jul; 6(7):1015-7. PubMed ID: 17611408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
    Tewari D; Saffari B; Cowan C; Wallick AC; Koontz MZ; Monk BJ
    Gynecol Oncol; 2006 Sep; 102(3):421-4. PubMed ID: 16797679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
    Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A
    J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
    Demetri GD; von Mehren M; Jones RL; Hensley ML; Schuetze SM; Staddon A; Milhem M; Elias A; Ganjoo K; Tawbi H; Van Tine BA; Spira A; Dean A; Khokhar NZ; Park YC; Knoblauch RE; Parekh TV; Maki RG; Patel SR
    J Clin Oncol; 2016 Mar; 34(8):786-93. PubMed ID: 26371143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
    Monk BJ; Blessing JA; Street DG; Muller CY; Burke JJ; Hensley ML
    Gynecol Oncol; 2012 Jan; 124(1):48-52. PubMed ID: 21996263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
    Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
    Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin.
    Grosso F; D'Incalci M; Cartoafa M; Nieto A; Fernández-Teruel C; Alfaro V; Lardelli P; Roy E; Gómez J; Kahatt C; Soto-Matos A; Judson I
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1557-65. PubMed ID: 22484722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
    Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG
    Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
    Theman TA; Hartzell TL; Sinha I; Polson K; Morgan J; Demetri GD; Orgill DP; George S
    J Clin Oncol; 2009 Nov; 27(33):e198-200. PubMed ID: 19805684
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
    Le Cesne A; Yovine A; Blay JY; Delaloge S; Maki RG; Misset JL; Frontelo P; Nieto A; Jiao JJ; Demetri GD
    Invest New Drugs; 2012 Jun; 30(3):1193-202. PubMed ID: 21484250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
    Blay JY; Casali P; Nieto A; Tanović A; Le Cesne A
    Future Oncol; 2014 Jan; 10(1):59-68. PubMed ID: 23987833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
    Tavella K; Villanucci A; Vannini L; Lavacchi D; Montelatici S; Amunni G; Mazzei T
    Anticancer Drugs; 2017 Apr; 28(4):465-468. PubMed ID: 28181940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma.
    Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A
    Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
    Bongiovanni A; Riva N; Ricci M; Mercatali L; Liverani C; La Manna F; De Vita A; Cavaliere D; Pieri F; Oboldi D; Verdecchia GM; Amadori D; Ibrahim T
    BMC Cancer; 2015 Dec; 15():998. PubMed ID: 26695071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
    Galizia D; Palesandro E; Nuzzo AM; Pignochino Y; Aliberti S; Aglietta M; Grignani G
    Oncol Res; 2013; 20(10):483-90. PubMed ID: 24308159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
    Martin-Liberal J; Judson I
    Expert Opin Drug Saf; 2013 Nov; 12(6):905-11. PubMed ID: 23937190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.